9PL Stock Chart & Stats
€0.01
>-€0.01(-9.09%)
At close: 4:00 PM EDT
€0.01
>-€0.01(-9.09%)
Day’s Range― - ―
52-Week Range<€0.01 - €0.08
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€8.33M
Enterprise Value€6.14
Total Cash (Recent Filing)€895.00K
Total Debt (Recent Filing)€146.00K
Price to Earnings (P/E)―
Beta12.54
Next Earnings
Sep 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding753,041,140
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)53.10
Price to Sales (P/S)2.14
P/FCF Ratio-1.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)€54.96K
Bulls Say, Bears Say
Bulls Say
Revenue GrowthImproving revenue growth indicates stronger commercial traction and product adoption. If sustained, greater scale could help GENinCode spread fixed operating costs and move closer to profitability, although current losses show that scale benefits have not yet materialized.
Gross Margin ImprovementA higher gross margin suggests better economics on products or services delivered and provides more revenue available to fund research, sales and administration. Maintaining this improvement would strengthen the pathway to eventual operating leverage as revenue expands.
Limited Absolute DebtSmall absolute debt reduces immediate interest and refinancing pressure compared with a heavily debt-funded business. This gives the company some balance-sheet flexibility, although the benefit is constrained by substantial losses, cash burn and sharply reduced equity.
Bears Say
Deep And Persistent UnprofitabilitySevere and continuing losses indicate that the current cost base is far too high for the company’s revenue scale. Without a durable improvement in operating efficiency or substantial revenue expansion, profitability remains uncertain and financial resources may continue to erode.
Persistent Cash BurnRepeated negative operating and free cash flow means the business is not funding itself internally. Continued cash consumption can require external financing, constrain investment capacity and increase dilution or liquidity risk unless cash breakeven is achieved.
Material Equity ErosionThe sharp fall in equity materially weakens financial resilience and reduces room to absorb further losses. Even with small total debt, the thinner equity base increases dependence on successful fundraising or operating improvement to preserve flexibility.
GENinCode UK Ltd. News
9PL FAQ
What was GENinCode UK Ltd.’s price range in the past 12 months?
GENinCode UK Ltd. lowest stock price was <€0.01 and its highest was €0.08 in the past 12 months.
What is GENinCode UK Ltd.’s market cap?
GENinCode UK Ltd.’s market cap is €8.33M.
When is GENinCode UK Ltd.’s upcoming earnings report date?
GENinCode UK Ltd.’s upcoming earnings report date is Sep 30, 2026 which is in 21 days.
How were GENinCode UK Ltd.’s earnings last quarter?
GENinCode UK Ltd. released its earnings results on Jun 08, 2026. The company reported -€0.012 earnings per share for the quarter.
Is GENinCode UK Ltd. overvalued?
According to Wall Street analysts GENinCode UK Ltd.’s price is currently Overvalued.
Does GENinCode UK Ltd. pay dividends?
GENinCode UK Ltd. does not currently pay dividends.
What is GENinCode UK Ltd.’s EPS estimate?
GENinCode UK Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does GENinCode UK Ltd. have?
GENinCode UK Ltd. has 753,041,140 shares outstanding.
What happened to GENinCode UK Ltd.’s price movement after its last earnings report?
GENinCode UK Ltd. reported an EPS of -€0.012 in its last earnings report. Following the earnings report the stock price went down -22.857%.
Which hedge fund is a major shareholder of GENinCode UK Ltd.?
Currently, no hedge funds are holding shares in DE:9PL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
GENinCode UK Ltd.
GENinCode Plc specializes in the creation and commercialization of advanced genetic tests designed to forecast potential health risks based on an individual's DNA. Operating in both the United Kingdom and internationally, their predictive technology empowers individuals and medical professionals alike with proactive health management and targeted intervention strategies. The company's sophisticated molecular diagnostics leverage a combination of clinical algorithms and artificial intelligence to deliver precise patient risk assessments, thereby anticipating the onset of various diseases. Among their specialized tests are: Cardio inCode: A patented genetic assay designed to guide individuals in cardiovascular prevention. Lipid inCode: A genetic diagnostic tool that analyzes seven specific genes associated with familial hypercholesterolemia. SUDD inCode: A genetic test to identify the underlying causes of sudden cardiac death and inherited heart conditions. Thrombo inCode: This test assesses 12 genetic variants linked to hereditary thrombophilia and the general risk of thrombosis (blood clots). Thrombo inCode Reproductive Health: Offering crucial insights into thrombophilia risks particularly relevant to prospective pregnancies. Established in 2018, GENinCode Plc maintains its headquarters in Oxford, United Kingdom.